Trial Profile
A phase II study of intravenous TZT-1027 [soblidotin] administerd weekly times two every three weeks to patients with advanced or metastatic soft tissue sarcomas (STS) with prior exposure to anthracycline-based chemotherapy
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 19 Feb 2024
Price :
$35
*
At a glance
- Drugs Soblidotin (Primary)
- Indications Haemangiosarcoma; Leiomyosarcoma; Liposarcoma; Paraganglioma; Rhabdomyosarcoma; Sarcoma; Synovial sarcoma
- Focus Therapeutic Use
- 30 Jul 2022 This trial has been discontinued in Germany, according to European Clinical Trials Database record.
- 15 May 2012 Actual end date (Dec 2005) added as reported by ClinicalTrials.gov.
- 23 Sep 2005 New trial record.